Increasing O-GlcNAc levels: An overview of small-molecule inhibitors of O-GlcNAcase

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 2, 2010, Pages 107-121

  Macauley, Matthew S ^a   Vocadlo, David J ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Enzyme inhibitor; Glycoprotein; Glycoside hydrolase; Nucleocytoplasmic glycosylation; O GlcNAc; O GlcNAcase; OGA; Substrate assisted catalysis

Indexed keywords

1 ACETAMIDO EPIVALIENAMINE; 1,2 DIDEOXY 2' METHYL ALPHA DEXTRO GLUCOPYRANOSO[2,1 D] DELTA 2' THIAZOLINE; ACETYLGLUCOSAMINIDASE; ENZYME INHIBITOR; GLUCOIMIDAZOLE DERIVATIVE; GLYCOSIDASE; GLYCOSIDASE INHIBITOR; N ACETYLGLUCOSAMINE; N ACETYLGLUCOSAMINE THIAZOLINE; N ACETYLGLUCOSAMINYLTRANSFERASE; N BUTYL THIAZOLINE; STREPTOZOCIN; THIAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

CATALYSIS; CELL STRESS; CYTOLOGY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; GENE OVEREXPRESSION; GLYCOSYLATION; HUMAN; IC 50; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION;

ACETYLGLUCOSAMINE; ACETYLGLUCOSAMINIDASE; ANIMALS; CATALYTIC DOMAIN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; N-ACETYLGLUCOSAMINYLTRANSFERASES; OXIMES; PHENYLCARBAMATES; PYRAZOLES; PYRIDINES; STREPTOZOCIN; THIAZOLES; URIDINE DIPHOSPHATE N-ACETYLGLUCOSAMINE;

EID: 77949305110     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.07.028     Document Type: Review

References (159)

1. Torres C.R., and Hart G.W. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J. Biol. Chem. 259 (1984) 3308-3317
2. Hart G.W., Housley M.P., and Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446 (2007) 1017-1022
3. Chou C.F., Smith A.J., and Omary M.B. Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18. J. Biol. Chem. 267 (1992) 3901-3906
4. Roquemore E.P., Chevrier M.R., Cotter R.J., and Hart G.W. Dynamic O-GlcNAcylation of the small heat shock protein alpha B-crystallin. Biochemistry 35 (1996) 3578-3586
5. Haltiwanger R.S., Holt G.D., and Hart G.W. Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase. J. Biol. Chem. 265 (1990) 2563-2568
6. Kreppel L.K., Blomberg M.A., and Hart G.W. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J. Biol. Chem. 272 (1997) 9308-9315
7. Dong D.L., and Hart G.W. Purification and characterization of an O-GlcNAc selective N-acetyl-beta-d-glucosaminidase from rat spleen cytosol. J. Biol. Chem. 269 (1994) 19321-19330
8. Gao Y., Wells L., Comer F.I., Parker G.J., and Hart G.W. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276 (2001) 9838-9845
9. Wang Z., Gucek M., and Hart G.W. Cross-talk between GlcNAcylation and phosphorylation: Site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc. Natl. Acad. Sci. USA 105 (2008) 13793-13798
10. Dong D.L., Xu Z.S., Chevrier M.R., Cotter R.J., Cleveland D.W., and Hart G.W. Glycosylation of mammalian neurofilaments. Localization of multiple O-linked N-acetylglucosamine moieties on neurofilament polypeptides L and M. J. Biol. Chem. 268 (1993) 16679-16687
11. Khidekel N., Ficarro S.B., Clark P.M., Bryan M.C., Swaney D.L., Rexach J.E., Sun Y.E., Coon J.J., Peters E.C., and Hsieh-Wilson L.C. Probing the dynamics of O-GlcNAc glycosylation in the brain using quantitative proteomics. Nat. Chem. Biol. 3 (2007) 339-348
12. Yki-Jarvinen H., Virkamaki A., Daniels M.C., McClain D., and Gottschalk W.K. Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. Metabolism 47 (1998) 449-455
13. Hazel M., Cooksey R.C., Jones D., Parker G., Neidigh J.L., Witherbee B., Gulve E.A., and McClain D.A. Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology 145 (2004) 2118-2128
14. Clark R.J., McDonough P.M., Swanson E., Trost S.U., Suzuki M., Fukuda M., and Dillmann W.H. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J. Biol. Chem. 278 (2003) 44230-44237
15. Housley M.P., Udeshi N.D., Rodgers J.T., Shabanowitz J., Puigserver P., Hunt D.F., and Hart G.W. A PGC-1{alpha}-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose. J. Biol. Chem. 284 (2009) 5148-5157
16. Cheung W.D., Sakabe K., Housley M.P., Dias W.B., and Hart G.W. O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J. Biol. Chem. 283 (2008) 33935-33941
17. Haltiwanger R.S., Grove K., and Philipsberg G.A. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate. J. Biol. Chem. 273 (1998) 3611-3617
18. Macauley M.S., Whitworth G.E., Debowski A.W., Chin D., and Vocadlo D.J. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. J. Biol. Chem. 280 (2005) 25313-25322
19. Yuzwa S.A., Macauley M.S., Heinonen J.E., Shan X., Dennis R.J., He Y., Whitworth G.E., Stubbs K.A., McEachern E.J., Davies G.J., and Vocadlo D.J. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 4 (2008) 483-490
20. Dorfmueller H.C., Borodkin V.S., Schimpl M., Shepherd S.M., Shpiro N.A., and van Aalten D.M. GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels. J. Am. Chem. Soc. 128 (2006) 16484-16485
21. Macauley M.S., Bubb A.K., Martinez-Fleites C., Davies G.J., and Vocadlo D.J. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J. Biol. Chem. 283 (2008) 34687-34695
22. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
23. Marshall S., Nadeau O., and Yamasaki K. Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes: differential effects on glucosamine 6-phosphate, UDP-N-acetylglucosamine, and ATP levels. J. Biol. Chem. 279 (2004) 35313-35319
24. Bosch R.R., Pouwels M.J., Span P.N., Olthaar A.J., Tack C.J., Hermus A.R., and Sweep C.G. Hexosamines are unlikely to function as a nutrient-sensor in 3T3-L1 adipocytes: a comparison of UDP-hexosamine levels after increased glucose flux and glucosamine treatment. Endocrine 23 (2004) 17-24
25. McKnight G.L., Mudri S.L., Mathewes S.L., Traxinger R.R., Marshall S., Sheppard P.O., and O'Hara P.J. Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase. J. Biol. Chem. 267 (1992) 25208-25212
26. Walgren J.L., Vincent T.S., Schey K.L., and Buse M.G. High glucose and insulin promote O-GlcNAc modification of proteins, including alpha-tubulin. Am. J. Physiol., Endocrinol. Metab. 284 (2003) E424-434
27. Robinson K.A., Ball L.E., and Buse M.G. Reduction of O-GlcNAc protein modification does not prevent insulin resistance in 3T3-L1 adipocytes. Am. J. Physiol., Endocrinol. Metab. 292 (2007) E884-890
28. Vosseller K., Wells L., Lane M.D., and Hart G.W. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA 99 (2002) 5313-5318
29. Hresko R.C., Heimberg H., Chi M.M., and Mueckler M. Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP. J. Biol. Chem. 273 (1998) 20658-20668
30. Marshall S., Yamasaki K., and Okuyama R. Glucosamine induces rapid desensitization of glucose transport in isolated adipocytes by increasing GlcN-6-P levels. Biochem. Biophys. Res. Commun. 329 (2005) 1155-1161
31. Matthews J.A., Belof J.L., Acevedo-Duncan M., and Potter R.L. Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells. Mol. Cell. Biochem. 298 (2007) 109-123
32. Lau K.S., Partridge E.A., Grigorian A., Silvescu C.I., Reinhold V.N., Demetriou M., and Dennis J.W. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129 (2007) 123-134
33. Ohtsubo K., Takamatsu S., Minowa M.T., Yoshida A., Takeuchi M., and Marth J.D. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 123 (2005) 1307-1321
34. Ohtsubo K., and Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 126 (2006) 855-867
35. McClain D.A., Lubas W.A., Cooksey R.C., Hazel M., Parker G.J., Love D.C., and Hanover J.A. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc. Natl. Acad. Sci. USA 99 (2002) 10695-10699
36. Iyer S.P., Akimoto Y., and Hart G.W. Identification and cloning of a novel family of coiled-coil domain proteins that interact with O-GlcNAc transferase. J. Biol. Chem. 278 (2003) 5399-5409
37. Iyer S.P., and Hart G.W. Roles of the tetratricopeptide repeat domain in O-GlcNAc transferase targeting and protein substrate specificity. J. Biol. Chem. 278 (2003) 24608-24616
38. Whisenhunt T.R., Yang X., Bowe D.B., Paterson A.J., Van Tine B.A., and Kudlow J.E. Disrupting the enzyme complex regulating O-GlcNAcylation blocks signaling and development. Glycobiology 16 (2006) 551-563
39. Slawson C., Lakshmanan T., Knapp S., and Hart G.W. A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin. Mol. Biol. Cell 19 (2008) 4130-4140
40. Gambetta M.C., Oktaba K., and Muller J. Essential role of the glycosyltransferase sxc/Ogt in polycomb repression. Science 325 (2009) 93-96
41. Sinclair D.R., Syrzycka M., Macauley M.S., Rastgardani R., Komljenovic I., Vocadlo D.J., Brock H.W., and Honda B.M. Drosophila O-GlcNAc transferase (OGT) is encoded by the Polycomb group (PcG) gene, super sex combs (sxc). Proc Natl Acad Sci U. S. A. 106 (2009) 13427-13432
42. Ingham P.W. A gene that regulates the bithorax complex differentially in larval and adult cells of Drosophila. Cell 37 (1984) 815-823
43. Schwartz Y.B., and Pirrotta V. Polycomb complexes and epigenetic states. Curr. Opin. Cell Biol. 20 (2008) 266-273
44. Fujiki R., Chikanishi T., Hashiba W., Ito H., Takada I., Roeder R.G., Kitagawa H., and Kato S. GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature 459 (2009) 455-459
45. Slawson C., Zachara N.E., Vosseller K., Cheung W.D., Lane M.D., and Hart G.W. Perturbations in O-linked beta-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis. J. Biol. Chem. 280 (2005) 32944-32956
46. Bowe D.B., Sadlonova A., Toleman C.A., Novak Z., Hu Y., Huang P., Mukherjee S., Whitsett T., Frost A.R., Paterson A.J., and Kudlow J.E. O-GlcNAc integrates the proteasome and transcriptome to regulate nuclear hormone receptors. Mol. Cell. Biol. 26 (2006) 8539-8550
47. Ngoh G.A., Facundo H.T., Hamid T., Dillmann W., Zachara N.E., and Jones S.P. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ. Res. 104 (2009) 41-49
48. Mayer T.U. Chemical genetics: tailoring tools for cell biology. Trends Cell Biol. 13 (2003) 270-277
49. Knight Z.A., and Shokat K.M. Chemical genetics: where genetics and pharmacology meet. Cell 128 (2007) 425-430
50. Arias E.B., Kim J., and Cartee G.D. Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes 53 (2004) 921-930
51. Akimoto Y., Hart G.W., Wells L., Vosseller K., Yamamoto K., Munetomo E., Ohara-Imaizumi M., Nishiwaki C., Nagamatsu S., Hirano H., and Kawakami H. Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats. Glycobiology 17 (2007) 127-140
52. Zou L., Yang S., Hu S., Chaudry I.H., Marchase R.B., and Chatham J.C. The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels. Shock 27 (2007) 402-408
53. Kanin E.I., Kipp R.T., Kung C., Slattery M., Viale A., Hahn S., Shokat K.M., and Ansari A.Z. Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis. Proc. Natl. Acad. Sci. USA 104 (2007) 5812-5817
54. Liu L.B., Omata W., Kojima I., and Shibata H. The SUMO conjugating enzyme Ubc9 is a regulator of GLUT4 turnover and targeting to the insulin-responsive storage compartment in 3T3-L1 adipocytes. Diabetes 56 (2007) 1977-1985
55. Broedl U.C., Maugeais C., Marchadier D., Glick J.M., and Rader D.J. Effects of nonlipolytic ligand function of endothelial lipase on high density lipoprotein metabolism in vivo. J. Biol. Chem. 278 (2003) 40688-40693
56. Martinez-Fleites C., Yuan H., and Davies G. Structural analyses of enzymes involved in the O-GlcNAc modification. Biochim. Biophys. Acta 1800 (2010) 122-133
57. Henrissat B., and Bairoch A. Updating the sequence-based classification of glycosyl hydrolases. Biochem. J. 316 (1996) 695-696
58. Toleman C., Paterson A.J., Whisenhunt T.R., and Kudlow J.E. Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities. J. Biol. Chem. 279 (2004) 53665-53673
59. Butkinaree C., Cheung W.D., Park S.J., Park K., Barber M., and Hart G.W. Characterization of beta-N-acetylglucosaminidase (O-GlcNAcase) cleavage by caspase-3 during apoptosis. J. Biol. Chem. 283 (2008) 23557-23566
60. Kim E.J., Kang D.O., Love D.C., and Hanover J.A. Enzymatic characterization of O-GlcNAcase isoforms using a fluorogenic GlcNAc substrate. Carbohydr. Res. 341 (2006) 971-982
61. Macauley M.S., and Vocadlo D.J. Enzymatic characterization and inhibition of the nuclear variant of human O-GlcNAcase. Carbohydr. Res. 344 (2009) 1079-1084
62. Comtesse N., Maldener E., and Meese E. Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. Biochem. Biophys. Res. Commun. 283 (2001) 634-640
63. Braidman I., Carroll M., Dance N., and Robinson D. Separation and properties of human brain hexosaminidase C. Biochem. J. 143 (1974) 295-301
64. Ueno R., and Yuan C.S. Purification and properties of neutral beta-N-acetylglucosaminidase from carp blood. Biochim. Biophys. Acta 1074 (1991) 79-84
65. Gutternigg M., Rendic D., Voglauer R., Iskratsch T., and Wilson I.B. Mammalian cells contain a second nucleocytoplasmic hexosaminidase. Biochem. J. 419 (2009) 83-90
66. Rao F.V., Dorfmueller H.C., Villa F., Allwood M., Eggleston I.M., and van Aalten D.M. Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis. EMBO J. 25 (2006) 1569-1578
67. Dennis R.J., Taylor E.J., Macauley M.S., Stubbs K.A., Turkenburg J.P., Hart S.J., Black G.N., Vocadlo D.J., and Davies G.J. Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity. Nat. Struct. Mol. Biol. 13 (2006) 365-371
68. Cetinbas N., Macauley M.S., Stubbs K.A., Drapala R., and Vocadlo D.J. Identification of Asp174 and Asp175 as the key catalytic residues of human O-GlcNAcase by functional analysis of site-directed mutants. Biochemistry 45 (2006) 3835-3844
69. Ficko-Blean E., Gregg K.J., Adams J.J., Hehemann J.H., Czjzek M., Smith S.P., and Boraston A.B. Portrait of an enzyme: A complete structural analysis of a multi-modular beta-N-acetylglucosaminidase from clostridium perfringens. J. Biol. Chem. 284 (2009) 9876-9884
70. Vocadlo D.J., and Davies G.J. Mechanistic insights into glycosidase chemistry. Curr. Opin. Chem. Biol. 12 (2008) 539-555
71. Dorfmueller H.C., Borodkin V.S., Schimpl M., and van Aalten D.M. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation. Biochem. J. 420 (2009) 221-227
72. Segel I.H. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (1993), Wiley-Interscience, New York
73. Carrillo L.D., Krishnamoorthy L., and Mahal L.K. A cellular FRET-based sensor for beta-O-GlcNAc, a dynamic carbohydrate modification involved in signaling. J. Am. Chem. Soc. 128 (2006) 14768-14769
74. Horsch M., Hoesch L., Vasella A., and Rast D.M. N-acetylglucosaminono-1, 5-lactone oxime and the corresponding (phenylcarbamoyl)oxime. Novel and potent inhibitors of beta-N-acetylglucosaminidase. Eur. J. Biochem. 197 (1991) 815-818
75. Miller D.J., Gong X., and Shur B.D. Sperm require beta-N-acetylglucosaminidase to penetrate through the egg zona pellucida. Development 118 (1993) 1279-1289
76. Triggs-Raine B., Mahuran D.J., and Gravel R.A. Naturally occurring mutations in GM2 gangliosidosis: a compendium. Adv. Genet. 44 (2001) 199-224
77. Yang X., Ongusaha P.P., Miles P.D., Havstad J.C., Zhang F., So W.V., Kudlow J.E., Michell R.H., Olefsky J.M., Field S.J., and Evans R.M. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 451 (2008) 964-969
78. Francisco H., Kollins K., Varghis N., Vocadlo D., Vosseller K., and Gallo G. O-GlcNAc post-translational modifications regulate the entry of neurons into an axon branching program. Dev. Neurobiol. 69 (2009) 162-173
79. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., and Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
80. Nojiri H., Stroud M., and Hakomori S. A specific type of ganglioside as a modulator of insulin-dependent cell growth and insulin receptor tyrosine kinase activity. Possible association of ganglioside-induced inhibition of insulin receptor function and monocytic differentiation induction in HL-60 cells. J. Biol. Chem. 266 (1991) 4531-4537
81. Kawabuchi M., Satomi Y., Takao T., Shimonishi Y., Nada S., Nagai K., Tarakhovsky A., and Okada M. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404 (2000) 999-1003
82. Stubbs K.A., Balcewich M., Mark B.L., and Vocadlo D.J. Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance. J. Biol. Chem. 282 (2007) 21382-21391
83. Ficko-Blean E., Stubbs K.A., Nemirovsky O., Vocadlo D.J., and Boraston A.B. Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc. Natl. Acad. Sci. USA 105 (2008) 6560-6565
84. Yogalingam G., and Hopwood J.J. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum. Mutat. 18 (2001) 264-281
85. Junod A., Lambert A.E., Orci L., Pictet R., Gonet A.E., and Renold A.E. Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med. 126 (1967) 201-205
86. Schnedl W.J., Ferber S., Johnson J.H., and Newgard C.B. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 43 (1994) 1326-1333
87. Bennett R.A., and Pegg A.E. Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 41 (1981) 2786-2790
88. Kroncke K.D., Fehsel K., Sommer A., Rodriguez M.L., and Kolb-Bachofen V. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol. Chem. Hoppe-Seyler 376 (1995) 179-185
89. Yamamoto H., Uchigata Y., and Okamoto H. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294 (1981) 284-286
90. Konrad R.J., Mikolaenko I., Tolar J.F., Liu K., and Kudlow J.E. The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic beta-cell O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase. Biochem. J. 356 (2001) 31-41
91. Roos M.D., Xie W., Su K., Clark J.A., Yang X., Chin E., Paterson A.J., and Kudlow J.E. Streptozotocin, an analog of N-acetylglucosamine, blocks the removal of O-GlcNAc from intracellular proteins. Proc. Assoc. Am. Physicians 110 (1998) 422-432
92. Hanover J.A., Lai Z., Lee G., Lubas W.A., and Sato S.M. Elevated O-linked N-acetylglucosamine metabolism in pancreatic beta-cells. Arch. Biochem. Biophys. 362 (1999) 38-45
93. Liu K., Paterson A.J., Konrad R.J., Parlow A.F., Jimi S., Roh M., Chin Jr. E., and Kudlow J.E. Streptozotocin, an O-GlcNAcase inhibitor, blunts insulin and growth hormone secretion. Mol. Cell. Endocrinol. 194 (2002) 135-146
94. Lee T.N., Alborn W.E., Knierman M.D., and Konrad R.J. The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-beta-d-glucosaminidase that contain amino acid residues essential for enzymatic activity. Biochem. Pharmacol. 72 (2006) 710-718
95. Pathak S., Dorfmueller H.C., Borodkin V.S., and van Aalten D.M. Chemical dissection of the link between streptozotocin, O-GlcNAc, and pancreatic cell death. Chem. Biol. 15 (2008) 799-807
96. He Y., Martinez-Fleites C., Bubb A., Gloster T.M., and Davies G.J. Structural insight into the mechanism of streptozotocin inhibition of O-GlcNAcase. Carbohydr. Res. 340 (2008) 627-631
97. Toleman C., Paterson A.J., Shin R., and Kudlow J.E. Streptozotocin inhibits O-GlcNAcase via the production of a transition state analog. Biochem. Biophys. Res. Commun. 340 (2006) 526-534
98. Gao Y., Parker G.J., and Hart G.W. Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells. Arch. Biochem. Biophys. 383 (2000) 296-302
99. Okuyama R., and Yachi M. Cytosolic O-GlcNAc accumulation is not involved in beta-cell death in HIT-T15 or Min6. Biochem. Biophys. Res. Commun. 287 (2001) 366-371
100. Kawauchi K., Araki K., Tobiume K., and Tanaka N. Loss of p53 enhances catalytic activity of IKK{beta} through O-linked {beta}-N-acetyl glucosamine modification. Proc. Natl. Acad. Sci. USA 106 (2009) 3431-3436
101. Yang W.H., Kim J.E., Nam H.W., Ju J.W., Kim H.S., Kim Y.S., and Cho J.W. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat. Cell Biol. 8 (2006) 1074-1083
102. Knapp S., Vocadlo D., Gao Z.N., Kirk B., Lou J.P., and Withers S.G. NAG-thiazoline, an N-acetyl-beta-hexosaminidase inhibitor that implicates acetamido participation. J. Am. Chem. Soc. 118 (1996) 6804-6805
103. Mark B.L., Mahuran D.J., Cherney M.M., Zhao D.L., Knapp S., and James M.N.G. Crystal structure of human beta-hexosaminidase B: Understanding the molecular basis of Sandhoff and Tay-Sachs disease. J. Mol. Biol. 327 (2003) 1093-1109
104. Vocadlo D.J., Hang H.C., Kim E.J., Hanover J.A., and Bertozzi C.R. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc. Natl. Acad. Sci. USA 100 (2003) 9116-9121
105. Whitworth G.E., Macauley M.S., Stubbs K.A., Dennis R.J., Taylor E.J., Davies G.J., Greig I.R., and Vocadlo D.J. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J. Am. Chem. Soc. 129 (2007) 635-644
106. Stubbs K.A., Macauley M.S., and Vocadlo D.J. A selective inhibitor Gal-PUGNAc of human lysosomal beta-hexosaminidases modulates levels of the ganglioside GM2 in neuroblastoma cells. Angew Chem., Int. Ed. 48 (2009) 1300-1303
107. Macauley M.S., Stubbs K.A., and Vocadlo D.J. O-GlcNAcase catalyzes cleavage of thioglycosides without general acid catalysis. J. Am. Chem. Soc. 127 (2005) 17202-17203
108. Remko M., Swart M., and Bickelhaupt F.M. Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorg. Med. Chem. 14 (2006) 1715-1728
109. Tallent M.K., Varghis N., Skorobogatko Y., Hernandez-Cuebas L., Whelan K., Vocadlo D.J., and Vosseller K. In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J. Biol. Chem. 284 (2009) 174-181
110. Knapp S., Abdo M., Ajayi K., Huhn R.A., Emge T.J., Kim E.J., and Hanover J.A. Tautomeric modification of GlcNAc-thiazoline. Org. Lett. 9 (2007) 2321-2324
111. Stubbs K.A., Zhang N., and Vocadlo D.J. A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase. Org. Biomol. Chem. 4 (2006) 839-845
112. Kim E.J., Perreira M., Thomas C.J., and Hanover J.A. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety. J. Am. Chem. Soc. 128 (2006) 4234-4235
113. Balcewich M.D., Stubbs K.A., He Y., James T.W., Davies G.J., Vocadlo D.J., and Mark B.L. Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ. Protein Sci. 18 (2009) 1541-1551
114. Aoyama T., Naganawa H., Suda H., Uotani K., Aoyagi T., and Takeuchi T. The structure of nagstatin, a new inhibitor of N-acetyl-beta-d-glucosaminidase. J. Antibiot. (Tokyo) 45 (1992) 1557-1558
115. Aoyagi T., Suda H., Uotani K., Kojima F., Aoyama T., Horiguchi K., Hamada M., and Takeuchi T. Nagstatin, a new inhibitor of N-acetyl-beta-d-glucosaminidase, produced by Streptomyces amakusaensis MG846-fF3. Taxonomy, production, isolation, physico-chemical properties and biological activities. J. Antibiot. (Tokyo) 45 (1992) 1404-1408
116. Terinek M., and Vasella A. Synthesis of N-acetylglucosamine-derived nagstatin analogues and their evaluation as glycosidase inhibitors. Helv. Chim. Acta. 88 (2005) 10-22
117. Shanmugasundaram B., Debowski A.W., Dennis R.J., Davies G.J., Vocadlo D.J., and Vasella A. Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor. Chem. Commun. (2006) 4372-4374
118. Scaffidi A., Stubbs K.A., Dennis R.J., Taylor E.J., Davies G.J., Vocadlo D.J., and Stick R.V. A 1-acetamido derivative of 6-epi-valienamine: an inhibitor of a diverse group of beta-N-acetylglucosaminidases. Org. Biomol. Chem. 5 (2007) 3013-3019
119. Marcelo F., He Y., Yuzwa S.A., Nieto L., Jimenez-Barbero J., Sollogoub M., Vocadlo D.J., Davies G.D., and Bleriot Y. Molecular basis for inhibition of GH84 glycoside hydrolases by substituted azepanes: conformational flexibility enables probing of substrate distortion. J. Am. Chem. Soc. 131 (2009) 5390-5392
120. Dehennaut V., Lefebvre T., Sellier C., Leroy Y., Gross B., Walker S., Cacan R., Michalski J.C., Vilain J.P., and Bodart J.F. O-linked N-acetylglucosaminyltransferase inhibition prevents G2/M transition in Xenopus laevis oocytes. J. Biol. Chem. 282 (2007) 12527-12536
121. van Putten J.P., and Krans H.M. Glucose as a regulator of insulin-sensitive hexose uptake in 3T3 adipocytes. J. Biol. Chem. 260 (1985) 7996-8001
122. Massillon D., Barzilai N., Chen W., Hu M., and Rossetti L. Glucose regulates in vivo glucose-6-phosphatase gene expression in the liver of diabetic rats. J. Biol. Chem. 271 (1996) 9871-9874
123. Federici M., Menghini R., Mauriello A., Hribal M.L., Ferrelli F., Lauro D., Sbraccia P., Spagnoli L.G., Sesti G., and Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106 (2002) 466-472
124. Crook E.D., Daniels M.C., Smith T.M., and McClain D.A. Regulation of insulin-stimulated glycogen synthase activity by overexpression of glutamine: fructose-6-phosphate amidotransferase in rat-1 fibroblasts. Diabetes 42 (1993) 1289-1296
125. Marshall S., Bacote V., and Traxinger R.R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 266 (1991) 4706-4712
126. Hanover J.A. Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J. 15 (2001) 1865-1876
127. Nemoto S., Fergusson M.M., and Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306 (2004) 2105-2108
128. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434 (2005) 113-118
129. Park S.Y., Ryu J., and Lee W. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp. Mol. Med. 37 (2005) 220-229
130. Dentin R., Hedrick S., Xie J., Yates III J., and Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science 319 (2008) 1402-1405
131. Zachara N.E., O'Donnell N., Cheung W.D., Mercer J.J., Marth J.D., and Hart G.W. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J. Biol. Chem. 279 (2004) 30133-30142
132. Cheung W.D., and Hart G.W. AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J. Biol. Chem. 283 (2008) 13009-13020
133. Taylor R.P., Parker G.J., Hazel M.W., Soesanto Y., Fuller W., Yazzie M.J., and McClain D.A. Glucose deprivation stimulates O-GlcNAc modification of proteins through up-regulation of O-linked N-acetylglucosaminyltransferase. J. Biol. Chem. 283 (2008) 6050-6057
134. Jones S.P., Zachara N.E., Ngoh G.A., Hill B.G., Teshima Y., Bhatnagar A., Hart G.W., and Marban E. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation 117 (2008) 1172-1182
135. Champattanachai V., Marchase R.B., and Chatham J.C. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am. J. Physiol., Cell Physiol. 292 (2007) C178-187
136. Xing D., Feng W., Not L.G., Miller A.P., Zhang Y., Chen Y.F., Majid-Hassan E., Chatham J.C., and Oparil S. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am. J. Physiol., Heart Circ. Physiol. 295 (2008) H335-H342
137. Champattanachai V., Marchase R.B., and Chatham J.C. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2. Am. J. Physiol., Cell Physiol. 294 (2008) C1509-C1520
138. Griffith L.S., and Schmitz B. O-linked N-acetylglucosamine levels in cerebellar neurons respond reciprocally to pertubations of phosphorylation. Eur. J. Biochem. 262 (1999) 824-831
139. Comer F.I., and Hart G.W. Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry 40 (2001) 7845-7852
140. Cheng X., Cole R.N., Zaia J., and Hart G.W. Alternative O-glycosylation/O-phosphorylation of the murine estrogen receptor beta. Biochemistry 39 (2000) 11609-11620
141. Chou T.Y., Hart G.W., and Dang C.V. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J. Biol. Chem. 270 (1995) 18961-18965
142. Liu F., Iqbal K., Grundke-Iqbal I., Hart G.W., and Gong C.X. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101 (2004) 10804-10809
143. Lefebvre T., Ferreira S., Dupont-Wallois L., Bussiere T., Dupire M.J., Delacourte A., Michalski J.C., and Caillet-Boudin M.L. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins-a role in nuclear localization. Biochim. Biophys. Acta 1619 (2003) 167-176
144. Vosseller K., Trinidad J.C., Chalkley R.J., Specht C.G., Thalhammer A., Lynn A.J., Snedecor J.O., Guan S., Medzihradszky K.F., Maltby D.A., Schoepfer R., and Burlingame A.L. O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol. Cell. Proteomics 5 (2006) 923-934
145. Khidekel N., Ficarro S.B., Peters E.C., and Hsieh-Wilson L.C. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. Proc. Natl. Acad. Sci. USA 101 (2004) 13132-13137
146. Wells L., Vosseller K., Cole R.N., Cronshaw J.M., Matunis M.J., and Hart G.W. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol. Cell. Proteomics 1 (2002) 791-804
147. Vosseller K., Hansen K.C., Chalkley R.J., Trinidad J.C., Wells L., Hart G.W., and Burlingame A.L. Quantitative analysis of both protein expression and serine / threonine post-translational modifications through stable isotope labeling with dithiothreitol. Proteomics 5 (2005) 388-398
148. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., and Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15 (1996) 6541-6551
149. Marz P., Stetefeld J., Bendfeldt K., Nitsch C., Reinstein J., Shoeman R.L., Dimitriades-Schmutz B., Schwager M., Leiser D., Ozcan S., Otten U., and Ozbek S. Ataxin-10 interacts with O-linked beta-N-acetylglucosamine transferase in the brain. J. Biol. Chem. 281 (2006) 20263-20270
150. Riu I.H., Shin I.S., and Do S.I. Sp1 modulates ncOGT activity to alter target recognition and enhanced thermotolerance in E. coli. Biochem. Biophys. Res. Commun. 372 (2008) 203-209
151. Majumdar G., Harmon A., Candelaria R., Martinez-Hernandez A., Raghow R., and Solomon S.S. O-glycosylation of Sp1 and transcriptional regulation of the calmodulin gene by insulin and glucagon. Am. J. Physiol., Endocrinol. Metab. 285 (2003) E584-591
152. Gao Y., Miyazaki J., and Hart G.W. The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 beta-cells. Arch. Biochem. Biophys. 415 (2003) 155-163
153. Staiano N., Everson R.B., Cooney D.A., Longnecker D.S., and Thorgeirsson S.S. Mutagenicity of d- and l-azaserine, 6-diazo-5-oxo-L-norleucine and N-(N-methyl-N-nitroso-carbamyl)-l-ornithine in the Salmonella test system. Mutat. Res. 79 (1980) 387-390
154. Wu F., Lukinius A., Bergstrom M., Eriksson B., Watanabe Y., and Langstrom B. A mechanism behind the antitumour effect of 6-diazo-5-oxo-l-norleucine (DON): disruption of mitochondria. Eur. J. Cancer 35 (1999) 1155-1161
155. Konrad R.J., Zhang F., Hale J.E., Knierman M.D., Becker G.W., and Kudlow J.E. Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferase. Biochem. Biophys. Res. Commun. 293 (2002) 207-212
156. Zhang H., Gao G., and Brunk U.T. Extracellular reduction of alloxan results in oxygen radical-mediated attack on plasma and lysosomal membranes. Apmis 100 (1992) 317-325
157. Gross B.J., Kraybill B.C., and Walker S. Discovery of O-GlcNAc transferase inhibitors. J. Am. Chem. Soc. 127 (2005) 14588-14589
158. Vale C., and Botana L.M. Marine toxins and the cytoskeleton: okadaic acid and dinophysistoxins. FEBS J. 275 (2008) 6060-6066
159. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934